LncRNA-SRLR induces the IL-6/STAT3 axis to induce sorafenib resistance in RCC, and lncRNA-SRLR inhibition sensitizes nonresponsive RCC cells to sorafenib treatment in vitro. This evidence concerns the gene IL6 and renal cell carcinoma.